Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer—20 Years of Progress
Open Access
- 1 January 2015
- journal article
- review article
- Published by Springer Nature in Molecular Medicine
- Vol. 21 (S1) , S25-S31
Abstract
Circulating tumor cells (CTC) may be defined as tumor- or metastasis-derived cells that are present in the bloodstream. The CTC pool in colorectal cancer (CRC) patients may include not only epithelial tumor cells, but also tumor cells undergoing epithelial-mesenchymal transition (EMT) and tumor stem cells. A significant number of patients diagnosed with early stage CRC subsequently relapse with recurrent or metastatic disease despite undergoing "curative" resection of their primary tumor. This suggests that an occult metastatic disease process was already underway, with viable tumor cells being shed from the primary tumor site, at least some of which have proliferative and metastatic potential and the ability to survive in the bloodstream. Such tumor cells are considered to be responsible for disease relapse in these patients. Their detection in peripheral blood at the time of diagnosis or after resection of the primary tumor may identify those early-stage patients who are at risk of developing recurrent or metastatic disease and who would benefit from adjuvant therapy. CTC may also be a useful adjunct to radiological assessment of tumor response to therapy. Over the last 20 years many approaches have been developed for the isolation and characterization of CTC. However, none of these methods can be considered the gold standard for detection of the entire pool of CTC. Recently our group has developed novel unbiased inertial microfluidics to enrich for CTC, followed by identification of CTC by imaging flow cytometry. Here, we provide a review of progress on CTC detection and clinical significance over the last 20 years.Keywords
This publication has 68 references indexed in Scilit:
- High-throughput single-microparticle imaging flow analyzerProceedings of the National Academy of Sciences, 2012
- Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transitionBMC Cancer, 2012
- Evaluation of the Adenocarcinoma-Associated Gene AGR2 and the Intestinal Stem Cell Marker LGR5 as Biomarkers in Colorectal CancerInternational Journal of Molecular Sciences, 2012
- Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes MetastasisCancer Cell, 2011
- Circulating Tumor Cell Isolation and Diagnostics: Toward Routine Clinical UseCancer Research, 2011
- Circulating Tumor Cells: Not All Detected Cells Are Bad and Not All Bad Cells Are DetectedJournal of Clinical Oncology, 2011
- Circulating tumour cells: their utility in cancer management and predicting outcomesTherapeutic Advances in Medical Oncology, 2010
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- Identification of stem cells in small intestine and colon by marker gene Lgr5Nature, 2007
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004